Marinus Pharmaceuticals (NASDAQ:MRNS) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report sent to investors on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

MRNS has been the subject of a number of other research reports. Oppenheimer raised shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a report on Monday, September 23rd. Jefferies Financial Group restated a “hold” rating and set a $0.50 target price (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Truist Financial cut Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. TD Cowen reissued a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Finally, Royal Bank of Canada reduced their target price on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research note on Friday, October 25th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Trading Down 0.4 %

MRNS opened at $0.54 on Tuesday. Marinus Pharmaceuticals has a 1-year low of $0.22 and a 1-year high of $10.50. The stock has a market capitalization of $29.97 million, a PE ratio of -0.22 and a beta of 1.03. The firm has a 50-day moving average price of $0.38 and a two-hundred day moving average price of $0.98.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Point72 DIFC Ltd acquired a new position in Marinus Pharmaceuticals during the second quarter worth $28,000. AQR Capital Management LLC increased its stake in shares of Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 12,934 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter valued at about $64,000. World Investment Advisors LLC acquired a new stake in Marinus Pharmaceuticals in the 3rd quarter valued at about $104,000. Finally, Squarepoint Ops LLC bought a new position in Marinus Pharmaceuticals during the second quarter worth about $206,000. 98.80% of the stock is currently owned by institutional investors and hedge funds.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.